Blood Proteins For Early Discrimination Of DEmentias
Funder
National Health and Medical Research Council
Funding Amount
$498,412.00
Summary
bPRIDE aims to develop blood biomarkers for early and specific diagnosis of the main dementia types: Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies, and use these to develop diagnostic tests.
Speech Impairment In Frontotemporal Dementia And Primary Progressive Aphasia
Funder
National Health and Medical Research Council
Funding Amount
$50,888.00
Summary
This research project aims to inform our understanding of the characteristics and trajectory of speech difficulties in frontotemporal dementia and primary progressive aphasia, two forms of younger onset dementia. Understanding the changes to speech that occur will assist with the early diagnosis of these disorders and improve measurement of disease progression. Findings will positively influence patient care through the identification of treatment targets and improved knowledge of prognosis.
DUAL AND MULTIPLE PROTEINOPATHIES IN NEURODEGENERATIVE DEMENTIAS – RISK FACTORS, PROGNOSTIC INDICATORS AND CLINICAL RAMIFICATIONS
Funder
National Health and Medical Research Council
Funding Amount
$604,644.00
Summary
Dementia is the umbrella term used to refer to a number of different clinical presentations,each associated with distinct histopathological signatures of protein aggregates and spread.However, converging evidence now suggests the common co-occurences of dual/multiple proteinopathies across dementia syndromes.The present study will identify the clinical ramifications and factors that are most predictive for such proteinopathies in a large cohort of longitudinally-studied patients with dementia.
Finding Clinical Predictors For The Underlying Pathology In Different Frontotemporal Dementia (FTD) Syndromes
Funder
National Health and Medical Research Council
Funding Amount
$136,593.00
Summary
Due to the ageing population in Australia it is predicted that the prevalence of dementia will increase four-fold by 2050. Developing disease-modifying therapies for dementia is therefore a priority, however we also need to be able to accurately identify patients for whom these therapies will be beneficial. Here we will develop strategies for identifying patients with particular protein abnormalities in their brain, the substrate of most therapeutic interventions.
In Vivo Tau Imaging In Alzheimer’s Disease And Other Dementias
Funder
National Health and Medical Research Council
Funding Amount
$538,998.00
Summary
Alteration of the normal protein tau leads to its deposition inside the brain cells leading to their death. These deposits have been well characterized and they are associated with cognitive impairment. We propose to study tau deposits in vivo in humans using positron emission tomography (PET) and assess its association with cognition and other signs of neurodegeneration
Apathy In Dementia: Identifying Mechanisms For Targeted Interventions
Funder
National Health and Medical Research Council
Funding Amount
$514,404.00
Summary
One of the most common symptoms in dementia is apathy - a reduction in concern, motivation or interest. Apathy impacts on a person’s ability to engage in necessary daily activities (e.g., cooking, washing, visiting friends) and often leads to people being placed in aged care facilities. This project will investigate the mechanisms which give rise to apathy in dementia. Understanding these mechanisms is the first step in developing new interventions to treat this challenging symptom.
Non-Alzheimer Dementia: Pathogenesis And Clinicopathological Correlations
Funder
National Health and Medical Research Council
Funding Amount
$437,036.00
Summary
Dementia affects as many as 20% of people in their eighties. Although much of this is caused by Alzheimer's disease (AD), other types of dementia are also important. In this study we will look at two types of non-Alzheimer dementia, frontotemporal dementia (FTD) and small vessel cerebrovascular disease (SVD). The clinical symptoms of SVD closely resemble AD. Conversely, FTD results in degeneration of those parts of the brain which are responsible for personality, behaviour and language. We will ....Dementia affects as many as 20% of people in their eighties. Although much of this is caused by Alzheimer's disease (AD), other types of dementia are also important. In this study we will look at two types of non-Alzheimer dementia, frontotemporal dementia (FTD) and small vessel cerebrovascular disease (SVD). The clinical symptoms of SVD closely resemble AD. Conversely, FTD results in degeneration of those parts of the brain which are responsible for personality, behaviour and language. We will look at the brains of patients who have died with these diseases and determine the types of neurons which are damaged and their distribution in the brain. We will also investigate whether an individual's genetic make-up influences the development of SVD. In addition, in collaboration with neuropathologists across Australia, we will develop and standardise criteria for the pathological diagnosis of these diseases. Overall, this study will better characterise the pathology of two commonly encountered non-AD dementias and provide valuable insights into their causes.Read moreRead less
Restoring Defective Protein Homeostasis In Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
Frontotemporal dementia (FTD) is associated with pathological accumulation and aggregation of toxic proteins in affected brain regions. This project will employ a novel high throughput drug screening platform technology, FTD patient-derived nerve cells and genetic mouse models to screen drugs to improve clearance of toxic proteins and nerve cell health. This approach should accelerate discovery of agents to potentially treat the underlying cause of FTD in an effort to slow disease progression.
Targeting Pathogenic TAR DNA-binding Protein 43 To Treat Frontotemporal Dementia And Motor Neuron Disease
Funder
National Health and Medical Research Council
Funding Amount
$687,444.00
Summary
Frontotemporal dementia and motor neuron Disease are rapidly progressive and fatal neurodegenerative diseases that affect people in their prime. Poor understanding of the processes that lead to these diseases have slowed drug development. Through innovative experimental design, we aim to decipher a novel disease mechanism that involves specific molecular interactions and translate these findings into new therapies for the diseases.